Little Life Left in Promega v. Life Technologies Dispute
November 17, 2017
Authored and Edited by Ashley M. Winkler; Kevin D. Rodkey; Elizabeth D. Ferrill
In Promega Corporation v. Life Technologies Corporation, Nos. 2013‑1011, ‑1029, ‑1376 (Fed. Cir. Nov. 3, 2017), on remand from the Supreme Court, the Federal Circuit reviewed its prior holdings and considered whether they were consistent with the Supreme Court’s opinion, which issued in February 2017.
As an initial matter, the Federal Circuit determined that the Supreme Court’s opinion did not affect its prior holdings relating to enablement, licensing, and active inducement. The Federal Circuit determined that two issues, however, required review.
First, the court reexamined its reversal of the district court’s grant of Life’s motion for JMOL that Promega failed to prove infringement. The court affirmed the district court’s JMOL decision because, in view of the Supreme Court’s holding relating to non-infringement under 35 U.S.C. § 271(f)(1), Promega’s evidence of worldwide sales was insufficient evidence to support Promega’s “narrow damages theory” of lost profits for infringement under § 271(a).
Second, the court reconsidered whether it correctly vacated the district court’s denial of Promega’s motion for a new trial on damages and infringement. The court again reversed its prior holding and affirmed the district court. The court explained that this “is an unusual case” because Promega will not receive a damages award after proving infringement. The court found that it was nevertheless proper in this case because Promega waived other damages theories, preventing recovery by abandoning potentially valid damages, by relying “exclusively on a damages theory that ultimately prove[d] unsuccessful.”
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.